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Supplementary Table 1. Main characteristics of included RCTs 
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CDD, continuous daily dosing; CI, confidence interval; IFN-α, interferon-alpha; mOS, median overall survival; mPFS, median progression-free survival; NR, not reached; 
ORR, objective response rate; RCTs, randomized controlled trials; 4/2, 4 weeks on 2 weeks off dosing 
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Supplementary Table 2. Main characteristics of included RWD studies 







(95 % CI) 
mOS, months  
(95 % CI) ORR, % 
Heng et al. [8] 2009 British Columbia, Canada Sunitinib 69 63 - 17.3 - 
Bamias et al. [9] 2010 Greek Oncology, HECOG Sunitinib 109 59 8.9 (6.4–11.4) 17.1 (13.7–20.6) 22.4 
Schnadig et al. 
[10] 




134 64 7.5 (5.3–11.6) 15.5 (12.3–24.0) 16.4 
De Giorgi et al. 
[11] 
2014 Italian oncology units Sunitinib 185 74 11.0 (8.7–14.6) 25.5 (17.2–31.7) 34.6 
Miyake et al. 
[12] 
2014 Japanese patients from institution Sunitinib 110 62.5 
 
7.8 33.2 27.3 
Sheng et al. [13] 2016 Chinese patients, Peking University 
Cancer Hospital 
Sunitinib 165 55 11 (9–14) 28 (19–33) 31.9 
Pan et al. [14] 2015 Changzheng and Changhai Hospital, 
China 
Sunitinib 50 62 9.4 - 14.0 
Tan et al. [15] 2015 National Cancer Centre Singapore 
Registry 
Sunitinib 127 58 7.9 (5.2–11.0) 16.5 (15.1–21.6) 32.5 
Day et al. [16] 2015 Australian academic hospitals Sunitinib 125 60.7 - 27.6 - 
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Poprach et al. 
[17] 












De Groot et al. 
[18] 
2016 PERCEPTION Dutch Cancer Registry Sunitinib 153 64 - 6.8 (5.8–8.8) - 
Zhang et al. 
[19] 












Maroun et al. 
[20] 
2017 French National Health Insurance 
claims database 
Sunitinib 238 64 8.7 (6.9–9.9) 14.7 (11.9–18.3) - 
Noize et al. [21] 2017 SANTORIN French Observational 
Cohort 
Sunitinib 302 62.3 8.4 (7.6–9.9) 23.6 (20.2–NR) 31.1 
Lalani et al. 
[22] 













CI, confidence interval; HECOG, Hellenic Cooperative Oncology Group; mOS, median overall survival; mPFS, median progression-free survival; NR, not reached; ORR, 
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Supplementary Fig. 1 Sensitivity analyses for mPFS 
 
mPFS, median progression-free survival; RCT, randomized controlled trial; RWD, real-world data
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Supplementary Fig. 2 Sensitivity analyses for mOS 
 
mOS, median overall survival; RCT, randomized controlled trial; RWD, real-world data 
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Supplementary Fig. 3 Sensitivity analyses for ORR 
 
 ORR, objective response rate; RCT, randomized controlled trial; RWD, real-world data. 
 
